Analytical validation of soluble fms-like tyrosine and placental growth factor assays on B·R·A·H·M·S KRYPTOR Compact Plus automated immunoassay platform

Chan, Siaw Li; Rana, Sarosh; Chinthala, Sireesha; Salahuddin, Saira; Yeo, Kiang-Teck J.

doi:10.1016/j.preghy.2017.12.009

Cited by 11 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several commercial assays are currently available. 102,116,[133][134][135][136][137][138][139] The head-to-head comparison suggests that their predictive performance is similar, 116,[133][134][135] but their respective numerical test thresholds are not interchangeable across platforms, [133][134][135] nor is the sample matrix. 140 It is therefore important to regard the manufacturer's instructions when using these tests.…”

Section: Use In Clinical Practicementioning

confidence: 99%

“…The development of more precise rapid automated assays for sFlt‐1 and PlGF has facilitated clinical research and, importantly, allowed widespread adoption of angiogenic factor testing in clinical practice. Several commercial assays are currently available 102,116,133–139 . The head‐to‐head comparison suggests that their predictive performance is similar, 116,133–135 but their respective numerical test thresholds are not interchangeable across platforms, 133–135 nor is the sample matrix 140 .…”

Section: Biomarker Studies In Preeclampsiamentioning

confidence: 99%

See 1 more Smart Citation

Translation of mechanistic advances in preeclampsia to the clinic: Long and winding road

Thadhani,

Cerdeira,

Karumanchi

2024

The FASEB Journal

View full text Add to dashboard Cite

As one of the leading causes of premature birth and maternal and infant mortality worldwide, preeclampsia remains a major unmet public health challenge. Preeclampsia and related hypertensive disorders of pregnancy are estimated to cause >75 000 maternal and 500 000 infant deaths globally each year. Because of rising rates of risk factors such as obesity, in vitro fertilization and advanced maternal age, the incidence of preeclampsia is going up with rates ranging from 5% to 10% of all pregnancies worldwide. A major discovery in the field was the realization that the clinical phenotypes related to preeclampsia, such as hypertension, proteinuria, and other adverse maternal/fetal events, are due to excess circulating soluble fms‐like tyrosine kinase‐1 (sFlt‐1, also referred to as sVEGFR‐1). sFlt‐1 is an endogenous anti‐angiogenic protein that is made by the placenta and acts by neutralizing the pro‐angiogenic proteins vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). During the last decade, this work has spawned a new era of molecular diagnostics for early detection of this condition. Antagonizing sFlt‐1 either by reducing production or blocking its actions has shown salutary effects in animal models. Further, in early‐stage human studies, the therapeutic removal of sFlt‐1 from maternal circulation has shown promise in delaying disease progression and improving outcomes. Recently, the FDA approved the first molecular test for preterm preeclampsia (sFlt‐1/PlGF ratio) for clinical use in the United States. Measuring serum sFlt‐1/PlGF ratio in the acute hospital setting may aid short‐term management, particularly regarding step‐up or step‐down of care, decision to transfer to settings better equipped to manage both the mother and the preterm neonate, appropriate timing of administration of steroids and magnesium sulfate, and in expectant management decisions. The test itself has the potential to save lives. Furthermore, the availability of a molecular test that correlates with adverse outcomes has set the stage for interventional clinical trials testing treatments for this disorder. In this review, we will discuss the role of circulating sFlt‐1 and related factors in the pathogenesis of preeclampsia and specifically how this discovery is leading to concrete advances in the care of women with preeclampsia.

show abstract